Sacral nerve stimulation devices market seen topping $2.5 billion by 2030

The sacral nerve stimulation devices market is projected to grow from $1.48 billion in 2025 to $2.54 billion by 2030, driven by rising urological disorders, aging populations and broader use of minimally invasive treatments. North America led the market in 2025, while Asia-Pacific is expected to grow fastest through 2030.

Why it matters: - Sacral nerve stimulation devices are becoming a bigger part of care for urinary incontinence and overactive bladder. - The market’s projected growth points to rising demand for minimally invasive, long-term continence management options. - The report’s forecast suggests more investment in implantable neuromodulation and personalized neurological therapies.

What happened: - The Business Research Company published a 2026 market report on sacral nerve stimulation devices. - The report says the global market was worth $1.48 billion in 2025 and is expected to rise to $1.65 billion in 2026. - The report forecasts the market will reach $2.54 billion by 2030. - The report links the outlook to an 11.5% CAGR in the historical period and an 11.4% CAGR in the forecast period. - North America was the largest regional market in 2025. - Asia-Pacific is expected to be the fastest-growing region through the forecast period.

The details: - Sacral nerve stimulation devices are implantable medical tools that send electrical impulses to nerves in the sacral region. - The devices are used to manage urinary incontinence and overactive bladder by modulating nerve signals. - The report cites rising incidence of urinary incontinence, an aging population, technological advances in neuromodulation, broader clinical acceptance and growth in urology specialty services as drivers of earlier growth. - The forecast period is supported by growing use of smart implantable devices, more outpatient neuromodulation procedures, stronger demand for long-term continence management and higher investment in bioelectronic medicine. - The report also points to growing adoption of implantable neuromodulation technologies, programmable stimulation systems and therapies tailored to individual patients. - A National Institute of Diabetes and Digestive and Kidney Diseases update in April 2024 said about 651,446 people aged 65 and older in the US are newly diagnosed each year with some form of urinary incontinence. - The report says the devices offer a minimally invasive treatment alternative for urinary and fecal incontinence. - The market coverage includes Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The company also highlighted new report features including market attractiveness scoring, total addressable market analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, and updated graphics and tables. - The report includes a free sample and the full market report.

Between the lines: - The forecast suggests sacral nerve stimulation is moving from a niche therapy toward broader use in chronic bladder-care management. - Faster growth in Asia-Pacific may reflect expanding access to specialty urology care and stronger adoption of advanced implantable devices. - The emphasis on outpatient procedures and programmable systems points to a market that is shifting toward less invasive and more customizable treatment.

What's next: - The market is expected to keep expanding through 2030 as more patients seek device-based treatment for urological disorders. - Continued development of implantable neuromodulation and bioelectronic medicine could support additional product innovation. - Providers and manufacturers are likely to focus on personalized therapies and expanded access in high-growth regions.